1 July 2024 - The July 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The July issue of the Schedule includes several new/revised listings of note:

• Anifrolumab (Saphnelo) - new medicine
• Cytosine arabinoside with daunorubicin (nanoparticle, liposomal) (Vyxeos) - new combination product
• Evolocumab (Repatha) - restriction change
• Melatonin (Slentyo) - new medicine
• Olaparib (Lynparza) - new indication

Read Summary of PBS changes